Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.21.1
Commitments and Contingencies (Details Narrative)
3 Months Ended
Nov. 03, 2020
Dec. 13, 2019
USD ($)
$ / shares
shares
Dec. 13, 2019
EUR (€)
shares
Mar. 31, 2021
USD ($)
Mar. 31, 2021
EUR (€)
Mar. 31, 2021
EUR (€)
Dec. 31, 2020
USD ($)
Total Long-Term Debt       $ 3,231,243      
Payments for future research and collobration       1,100,000      
Short term lease costs       15,647      
Aggerate amount payable, description the Company to pay in aggregate of up to $2.9 million over a period of 22 months.            
Operating lease right-of-use assets       303,548     $ 326,085
Operating Lease Right of Use Obligations [Member]              
Short term lease costs       $ 309,379      
Weighted average discount rate       4.49%   4.49%  
Weighted average remaining lease term       29 months 29 months    
Operating lease right-of-use assets       $ 303,548      
Payment of lease liabilities       21,562      
Operating lease expense       21,488      
Managing Director's Agreement [Member]              
Amount payable       $ 229      
Transaction agreement description       In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing. In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing.    
Royalty payment       $ 126,829      
Royality       6.00% 6.00%    
Stock based compensation expenses       $ 753,000      
On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member]              
Total long-term debt       21,482      
Repayment of long-term loan amount | €         € 54,879    
In 2019 [Member] | Taxes A&M University [Member]              
Repayment of long-term loan amount       $ 400,000      
Loan agreement term       5 years 5 years    
Collaborative obligations amount due       $ 235,036      
In 2018 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | Namur Innovation and Growth [Member]              
Total long-term debt       $ 219,184      
Repayment of long-term loan amount | €         € 500,000    
Loan agreement term       4 years 4 years    
Fixed interest rate       4.00%   4.00%  
Maturity date       Jun. 30, 2022 Jun. 30, 2022    
In 2018 [Member] | Finance Lease Obligations [Member] | BNP Paribas leasing solutions [Member]              
Purchase price for the property | €           € 25,000  
Maturity date       Jan. 31, 2022 Jan. 31, 2022    
Amount payable       $ 8,826      
Implicit interest       1.35%   1.35%  
Leased equipment amortized term       5 years 5 years    
October 25, 2019 [Member] | TAMU [Member]              
Non-controlling interest       7.50% 7.50%    
Equity interest       12.50% 12.50%    
Additional interest       5.00% 5.00%    
January 10, 2020 [Member]              
Common stock, restricted shares issued in exchange of purchased outstanding shares, value   $ 333,969          
Restricted shares issued | shares   73,263 73,263        
Common stock, restricted shares issued in exchange of purchased outstanding shares, shares | shares   73,263 73,263        
Weighted trading price per share | $ / shares   $ 4.56          
Repayment of debt | €     € 350,000        
Common stock adjusted amount   $ 357,000          
Holdback period       9 months 9 months    
Holdback liabilities       $ 55,404      
Net liabilities   $ 43,152          
In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member]              
Collaborative obligations amount due       $ 96,000      
Research collaboration agreement description       The Company entered into a research collaboration agreement with the University of Taiwan to collect a total of 1,200 samples for a 2-year period for a cost to the Company of up to $320,000 payable over such period The Company entered into a research collaboration agreement with the University of Taiwan to collect a total of 1,200 samples for a 2-year period for a cost to the Company of up to $320,000 payable over such period    
ING [Member] | In 2016 [Member] | Long-term Debt [Member]              
Fixed interest rate on lease       2.62%   2.62%  
Lease payable       $ 612,599      
Purchase price for the property | €           € 1,120,000  
ING [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]              
Total long-term debt       $ 240,838      
Repayment of long-term loan amount | €         € 270,000    
Loan agreement term       15 years 15 years    
Fixed interest rate       2.62%   2.62%  
Maturity date       Dec. 31, 2031 Dec. 31, 2031    
Namur [Member] | October 13, 2020 [Member] | Long-term Debt [Member] | Loan Agreement [Member]              
Total long-term debt       $ 974,706      
Borrowed amount | €         € 65,453    
Repayment of long-term loan amount | €         € 830,000    
Loan agreement term       10 years 10 years    
Fixed interest rate       4.00%   4.00%  
Maturity date       Mar. 31, 2021 Mar. 31, 2021    
Namur Invest [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]              
Total long-term debt       $ 238,568      
Repayment of long-term loan amount | €         € 440,000    
Loan agreement term       7 years 7 years    
Fixed interest rate       4.85%   4.85%  
Maturity date       Dec. 31, 2023 Dec. 31, 2023    
Namur Invest [Member] | In 2019 [Member] | Long-term Debt [Member] | Loan Agreement [Member]              
Total long-term debt       $ 587,171      
Repayment of long-term loan amount | €         € 500,000    
Loan agreement term       4 years 4 years    
Fixed interest rate       4.80%   4.80%  
Maturity date       Sep. 30, 2024 Sep. 30, 2024    
Namur Invest [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member]              
Total long-term debt       $ 31,302      
Repayment of long-term loan amount | €         € 350,000    
Loan agreement term       4 years 4 years    
Fixed interest rate       4.00%   4.00%  
Maturity date       Jun. 30, 2021 Jun. 30, 2021    
SOFINEX [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member]              
Total long-term debt       $ 939,474      
Repayment of long-term loan amount | €         € 1,000,000    
Loan agreement term       7 years 7 years    
Fixed interest rate       4.50%   4.50%  
Maturity date       Sep. 30, 2024 Sep. 30, 2024    
Walloon Region Government [Member] | In 2010 [Member]              
Repayment of long-term loan amount | €         € 315,788    
Amount payable       $ 102,645      
Grant receivable | €           € 1,050,000  
Repayment of grants | €           314,406  
Terms of agreement description       it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received. it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received.    
Walloon Region Government [Member] | In 2018 [Member] | Colorectal Cancer Research Agreement [Member]              
Amount payable       $ 213,143      
Grant receivable | €           605,000  
Repayment of grants | €           181,500  
Terms of agreement description       It is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. It is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received.    
DKFZ [Member] | In 2016 [Member] | Research Co-operation Agreement [Member]              
Collaborative obligations amount due       $ 234,869      
Lease agreement expire period       5 years 5 years    
Collaborative obligations amount | €           € 400,000  
University of Taiwan [Member] | In 2018 [Member] | Clinical Study Research Agreement [Member]              
Collaborative obligations amount due       $ 510,000      
Lease agreement expire period       3 years 3 years    
Collaborative obligations amount       $ 2,550,000